Business
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting
ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD)
About this update from Abcellera Biologics Inc.
[{"type":"text","content":"\n\nABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD)\n\n\nIn preclinical studies, ABCL575 shows potent inhibition of inflammatory pathways, favorable in vivo pharmacokinetics (PK), and potential for less frequent dosing compared to a clinical benchmark\n\n\n \n\n VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California.\n\nAbCellera’s presentation, which is available for viewing here, describes key properties of ABCL575, including:\n\n\nPotent functional activity that is equivalent to the most advanced clinical benchmark, with inhibition of OX40L signalling and T-cell activation in vitro and significant reduction of Th2 cytokines in vivo.\n\n\nModified Fc domain that supports Fc-silencing and half-life extension, with a predicted human half-life of more than 60 days from preclinical in vivo PK data.\n\n\nPositive nonclinical safety profile and favorable stability when formulated at high concentration.\n\n\n\"We are encouraged by our preclinical data, which show high potency and a predicted extended half-life, demonstrating potential for ABCL575 to be a best-in-class treatment for people with atopic dermatitis,\" said Geoff Nichol, MB ChB, SVP, Development at AbCellera. “We look forward to advancing this molecule into the clinic and are on track to do so this year.”\n\nDetails on AbCellera’s poster presentation at SID are as follows:\n\nTitle: Preclinical development of ABCL575, a half-life extended anti-OX40L monoclonal antibody for the treatment of autoimmune conditions\nAbstract Number: 0980\nSession: Translational Studies: Preclinical\nDate and Time: Friday, May 9, from 4:30 p.m. to 6:00 p.m. PT\nLocation: Indigo Ballroom & Foyer\n\nAbout ABCL575\n\nABCL575 is a fully human, half-life extended anti-OX40L monoclonal antibody being investigated for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. Antibody-mediated blockade of OX40/OX40L signaling is a clinically validated mechanism to modulate inflammation. Targeting OX40L, an u...